Alectinib developed by Hoffmann-La Roche is used to treat which type of cancer?
Alectinib: Alectinib (INN, marketed as Alecensa) is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK) and is used to treat non-small-cell lung cancer (NSCLC). Alectinib:  It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group. Hoffmann-La Roche: F. Hoffmann-La Roche AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics.
non-small-cell lung cancer